scispace - formally typeset
D

Dimitrios Farmakiotis

Researcher at Brown University

Publications -  127
Citations -  4768

Dimitrios Farmakiotis is an academic researcher from Brown University. The author has contributed to research in topics: Polycystic ovary & Cancer. The author has an hindex of 28, co-authored 113 publications receiving 3481 citations. Previous affiliations of Dimitrios Farmakiotis include Veterans Health Administration & Rhode Island Hospital.

Papers
More filters
Journal ArticleDOI

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

Nicole M. Kuderer, +239 more
- 20 Jun 2020 - 
TL;DR: The outcomes of a cohort of patients with cancer and COVID-19 are characterised and potential prognostic factors for mortality and severe illness are identified and race and ethnicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality.
Journal ArticleDOI

Anti-Müllerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels

TL;DR: Comparison of anti-Müllerian hormone levels among obese or overweight and normal-weight women with the four different polycystic ovary syndrome phenotypes and healthy control subjects found differences in circulating AMH levels appear to reflect the severity of the syndrome, but are negatively affected by obesity.
Journal ArticleDOI

Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis

TL;DR: After controlling for BMI-related effects, adiponectin levels seem to be lower in women with PCOS compared with non-PCOS controls, and low levels of adiponECTin in PCOS are probably related to IR but not to testosterone.
Journal ArticleDOI

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.

Petros Grivas, +128 more
- 01 Jun 2021 - 
TL;DR: In this article, the authors analyzed a cohort of patients with cancer and coronavirus 2019 (COVID-19) reported to the COVID19 and Cancer Consortium (CCC19) to identify prognostic clinical factors, including laboratory measurements and anticancer therapies.